<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cerebral protection means prevention of cerebral neuronal damage </plain></SENT>
<SENT sid="1" pm="."><plain>Severe brain damage extinguishes the very "human" functions such as speech, consciousness, intellectual capacity, and emotional integrity </plain></SENT>
<SENT sid="2" pm="."><plain>Many pathologic conditions may inflict injuries to the brain, therefore the protection and salvage of cerebral neuronal function must be the top priorities in the care of <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Brain tissue has unusually high energy requirements, its stores of energy metabolites are small and, as a result, the brain is totally dependent on a continuous supply of substrates and oxygen, via the circulation </plain></SENT>
<SENT sid="4" pm="."><plain>In complete global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (<z:hpo ids='HP_0001695'>cardiac arrest</z:hpo>) reperfusion is characterized by an immediate reactive hyperemia followed within 20-30 min by a delayed hypoperfusion state </plain></SENT>
<SENT sid="5" pm="."><plain>It has been postulated that the latter contributes to the ultimate neurologic outcome </plain></SENT>
<SENT sid="6" pm="."><plain>In focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (<z:hpo ids='HP_0001297'>stroke</z:hpo>) the primary focus of <z:mp ids='MP_0001651'>necrosis</z:mp> is encircled by an area (ischemic penumbra) that is underperfused and contains neurotoxic substances such as free radicals, <z:chebi fb="11" ids="26333">prostaglandins</z:chebi>, calcium, and excitatory <z:chebi fb="65" ids="25512">neurotransmitters</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>The variety of therapeutic effort that have addressed the question of protecting the brain reflects their limited success </plain></SENT>
<SENT sid="8" pm="."><plain>1) <z:chebi fb="25" ids="22693">Barbiturates</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>After an initial enthusiastic endorsement by many clinicians and years of vigorous controversy, it can now be unequivocally stated that there is no place for <z:chebi fb="8" ids="29745">barbiturate</z:chebi> therapy following resuscitation from <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>One presumed explanation for this negative statement is that cerebral metabolic suppression by <z:chebi fb="25" ids="22693">barbiturates</z:chebi> (and other <z:chebi fb="37" ids="38867">anesthetics</z:chebi>) is impossible in the absence of an active EEG </plain></SENT>
<SENT sid="11" pm="."><plain>Conversely, in the event of incomplete <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> EEG activity in usually present (albeit altered) and metabolic suppression and hence possibly protection can be induced with <z:chebi fb="25" ids="22693">barbiturates</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Indeed, most of the animal studies led to a number of recommendations for <z:chebi fb="8" ids="29745">barbiturate</z:chebi> therapy in man for incomplete <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>2) <z:chebi fb="0" ids="6015">Isoflurane</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>From a cerebral metabolic standpoint, exposure to <z:chebi fb="0" ids="6015">isoflurane</z:chebi> at concentration of 2 MAC is credited with providing the same potential for protection as high dose <z:chebi fb="8" ids="29745">barbiturate</z:chebi> (isoelectric EEG) </plain></SENT>
<SENT sid="15" pm="."><plain>A possible major difference between <z:chebi fb="25" ids="22693">barbiturates</z:chebi> and <z:chebi fb="0" ids="6015">isoflurane</z:chebi> is the modest cerebral vasodilation induced by the latter while <z:chebi fb="25" ids="22693">barbiturates</z:chebi> are associated with decreased CBF </plain></SENT>
<SENT sid="16" pm="."><plain>This suggests that in focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:chebi fb="0" ids="6015">isoflurane</z:chebi> may elicit an intracerebral steal </plain></SENT>
<SENT sid="17" pm="."><plain>3) Calcium entry blockers </plain></SENT>
<SENT sid="18" pm="."><plain>Some calcium entry blockers with the distinctive feature of acting preferably on cerebral as opposed to systemic vascular smooth muscles may exert beneficial effects during or after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="19" pm="."><plain>Two such drugs which have shown promise are nimodipine and lidoflazine </plain></SENT>
<SENT sid="20" pm="."><plain>In animal and human studies nimodipine has been reported to improve the neurologic outcome of both the <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and the postischemic hypoperfusion state.(ABSTRACT TRUNCATED AT 400 WORDS) </plain></SENT>
</text></document>